Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Precision BioSciences Shares Skyrocket 30% in 2 Days Since Other

Precision BioSciences Reports 100% pgRNA Loss in HBV Trial; Advances to Phase 2

+30.54% in 2 days $8.12 when we broke this story → $10.60 at 8:32 AM ET, 9 Nov 2026

Precision BioSciences announced successful Phase 1 results for its PBGENE-HBV program, achieving 100% pgRNA loss to undetectable levels in patients at the target dose. The company also confirmed that its Duchenne muscular dystrophy candidate, PBGENE-DMD, successfully cleared its initial eight-week safety observation period.

Puzzle, dna, research, genetic. Stock photo illustrating Precision BioSciences' other story.
PRECISION BIOSCIENCES INC · Healthcare · Photo: qimono / Pixabay

Key highlights

  • PBGENE-HBV achieved 100% pgRNA loss to undetectable levels at the 0.4 mg/kg dose
  • Liver biopsy data demonstrated evidence of cccDNA elimination with reductions up to 1.5-log
  • Company is advancing the PBGENE-HBV program into a global Phase 2 study
  • First PBGENE-DMD patient completed safety observation with no serious adverse events reported
  • Cash runway is projected to fund operations through 2028 following recent capital initiatives

Advancing Chronic Hepatitis B Treatment

Precision BioSciences reported breakthrough Phase 1 clinical data for PBGENE-HBV, the first in vivo gene editing therapy designed to target the root cause of chronic hepatitis B. The ELIMINATE-B study results showed that 100% of evaluable patients receiving the 0.4 mg/kg dose achieved undetectable levels of pregenomic RNA (pgRNA). This biomarker is a critical indicator of the activity of covalently closed circular DNA (cccDNA), which maintains chronic infection. Evidence from liver biopsies further supported the elimination of cccDNA, showing reductions between 1-log and 1.5-log. Based on these findings, the company plans to progress the candidate into Phase 2 trials to evaluate viral cure rates.

Clinical Trial Milestones

  • Phase 1 ELIMINATE-B study successfully evaluated 25 patients across 59 administrations
  • No dose-limiting toxicities were reported, demonstrating a manageable safety profile
  • HBeAg-positive patients showed consistent pgRNA loss from high baseline copy levels
  • PBGENE-DMD Phase 1/2 trial received DSMB endorsement to proceed with additional patient dosing
  • DMD program safety observation completed eight weeks without adverse events of special interest

Business Overview and ARCUS Platform

Precision BioSciences utilizes its proprietary ARCUS genome editing platform to develop therapies for complex genetic diseases and infectious conditions. Unlike first-generation editing technologies, ARCUS is derived from a natural genome editing enzyme, I-CreI, designed for high specificity and the ability to perform complex genetic modifications. The company’s pipeline focuses on in vivo applications, where editing occurs directly within the patient’s body. This approach is currently being applied to chronic hepatitis B and Duchenne muscular dystrophy, aiming to provide permanent therapeutic solutions by addressing underlying genetic drivers rather than just managing symptoms.

Financial Context and Market Reaction

Following the clinical update, shares of Precision BioSciences (DTIL) rose 16.5% to $8.12. The company maintains a market capitalization of approximately $226.8 million with a trailing twelve-month revenue of $34.3 million. Recent financial disclosures indicate a strong liquidity position, with a cash runway expected to support operating requirements through 2028. This capital stability is bolstered by a $125 million underwritten public offering scheduled to close in early November 2026. Management has indicated that current resources are sufficient to reach multiple clinical readouts across the primary gene editing pipeline.

PRECISION BIOSCIENCES INC share price · last month
Line chart of PRECISION BIOSCIENCES INC's share price over the last month, from $6.19 on 19 Oct → $7.28 on 16 Nov; our story on 5 Nov at $8.12.

Down 10.3% since our story on 5 Nov: $8.12 when we broke it → $7.28 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$6.19
20 Oct$6.56
21 Oct$6.71
22 Oct$6.78
23 Oct$6.64
26 Oct$6.41
27 Oct$6.79
28 Oct$7.47
29 Oct$7.44
30 Oct$7.06
2 Nov$6.95
3 Nov$6.97
4 Nov$8.12
5 Nov$9.87
6 Nov$10.60
9 Nov$9.68
10 Nov$9.50
11 Nov$9.15
12 Nov$8.04
13 Nov$7.57
16 Nov$7.28
Earlier announcements by PRECISION BIOSCIENCES INC
DateAnnouncementAmount
03 Nov 2026Third quarter 2026 financial results and business updateSource: streetinsider.com–
24 Aug 2026Commenced dosing of first patient in Phase 1/2 FUNCTION-DMD trial of PBGENE-DMDSource: SEC filing–
06 Aug 2026Second quarter 2026 financial results and business updateSource: SEC filing–

Management commentary

“The new clinical data from ELIMINATE-B represent a breakthrough in our efforts to address the underlying cause of chronic hepatitis B, cccDNA. The consistency of the findings at the 0.4 mg/kg dose, including complete and durable pgRNA loss to undetectable levels, reproducible liver biopsies demonstrating evidence of cccDNA elimination, and a treatment effect in all patients with a manageable safety profile, supports advancement to a global Phase 2 study.”

Michael Amoroso, President and Chief Executive Officer
PRECISION BIOSCIENCES INC · financial snapshot
Share price$8.12
Market cap$227M
Revenue (annual)$34M
P/E (TTM)32.5×
1-month price change+28.68%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Precision BioSciences, Inc. announcing successful Phase 1 results for PBGENE-HBV and a safety update for PBGENE-DMD.

Read the filing ↗

Track PRECISION BIOSCIENCES INC live

Get the next PRECISION BIOSCIENCES INC SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.